Literature DB >> 16818956

Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients.

Neeta Pandit-Taskar1, Lawrence T Dauer, Leslie Montgomery, Jean St Germain, Pat B Zanzonico, Chaitanya R Divgi.   

Abstract

UNLABELLED: The purpose of this retrospective study was to determine whether lymphoscintigraphy (LSG) for sentinel lymph node (SNL) mapping in a woman with a breast mass presents an unacceptable risk to her fetus. We assessed radiation-absorbed dose to various organs from 99mTc-sulfur colloid (TSC) LSG using standard internal absorbed dose assessment methodologies for both reference phantoms as well as for phantom models using the specific patient population characteristics such as total body and injected organ mass. The study also projected the radiation-absorbed dose to the fetus from LSG for SLN mapping.
METHODS: Data from 1,021 nonpregnant women with early-stage breast cancer who underwent SLN mapping and biopsy procedures were analyzed. Patients had a single-site intradermal injection of unfiltered TSC in 0.05 mL normal saline: 3.7 MBq (0.1 mCi) on the morning of surgery (1-d protocol) or 18.5 MBq (0.5 mCi) on the afternoon before surgery (2-d protocol). A standard internal dose calculation methodology was used to calculate absorbed doses to various organs and to a modeled fetus at 3-, 6-, and 9-mo gestation from the injection site as well as from systemic activity.
RESULTS: The highest estimated absorbed doses were observed for the reference 9-mo-pregnant model under the 2-d protocol. Absorbed doses of 14.9, 0.214, 0.062, 0.151, 0.004, 0.163, 0.075, and 0.014 mGy were received by the injected breast, heart, liver, lung, ovaries, thymus, total body, and fetus, respectively. Effective doses from the 2-d protocol were estimated to be 0.460, 0.186, and 0.245 mSv for the reference population, the total Memorial Sloan-Kettering Cancer Center (MSKCC) study patient population, and childbearing-age MSKCC patient population (i.e., <45 y old), respectively.
CONCLUSION: SLN procedures lead to a negligible dose to the fetus of 0.014 mGy or less. This is much less than the National Council on Radiation Protection and Measurements limit to a pregnant woman. Calculations using actual patient population characteristics resulted in lower organ dose estimates than more conservative reference models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818956

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

Review 1.  Clinically Approved Nanoparticle Imaging Agents.

Authors:  Avnesh S Thakor; Jesse V Jokerst; Pejman Ghanouni; Jos L Campbell; Erik Mittra; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2016-10-13       Impact factor: 10.057

Review 2.  The evolution of the locoregional therapy of breast cancer.

Authors:  Alice Ho; Monica Morrow
Journal:  Oncologist       Date:  2011-09-29

3.  Sentinel lymph node biopsy in pregnant patients with breast cancer.

Authors:  Oreste Gentilini; Marta Cremonesi; Antonio Toesca; Nicola Colombo; Fedro Peccatori; Roberto Sironi; Claudia Sangalli; Nicole Rotmensz; Guido Pedroli; Giuseppe Viale; Paolo Veronesi; Viviana Galimberti; Aron Goldhirsch; Umberto Veronesi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

4.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

Review 5.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

6.  A proposal for the timing of management of patients with melanoma presenting during pregnancy.

Authors:  Niclas Broer; Samuel Buonocore; Carolyn Goldberg; Carolyn Truini; Marc B Faries; Deepak Narayan; Stephan Ariyan
Journal:  J Surg Oncol       Date:  2012-02-13       Impact factor: 3.454

7.  Fetal doses to pregnant patients from CT with tube current modulation calculated using Monte Carlo simulations and realistic phantoms.

Authors:  Jianwei Gu; X George Xu; Peter F Caracappa; Bob Liu
Journal:  Radiat Prot Dosimetry       Date:  2012-12-06       Impact factor: 0.972

8.  Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer.

Authors:  Nikita M Shah; Dana M Scott; Pridvi Kandagatla; Molly B Moravek; Erin F Cobain; Monika L Burness; Jacqueline S Jeruss
Journal:  Ann Surg Oncol       Date:  2019-01-24       Impact factor: 5.344

9.  The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Francesco Giammarile; Naomi Alazraki; John N Aarsvold; Riccardo A Audisio; Edwin Glass; Sandra F Grant; Jolanta Kunikowska; Marjut Leidenius; Valeria M Moncayo; Roger F Uren; Wim J G Oyen; Renato A Valdés Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

10.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  L W T Alkureishi; Z Burak; J A Alvarez; J Ballinger; A Bilde; A J Britten; L Calabrese; C Chiesa; A Chiti; R de Bree; H W Gray; K Hunter; A F Kovacs; M Lassmann; C R Leemans; G Mamelle; M McGurk; J Mortensen; T Poli; T Shoaib; P Sloan; J A Sorensen; S J Stoeckli; J B Thomsen; G Trifiro; J Werner; G L Ross
Journal:  Ann Surg Oncol       Date:  2009-11       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.